Method for carrying out non-isotopic immunoassays, labeled analytes and kits for use in such assays

• US 4,378,428 A
• Filed: 03/30/1981
• Issued: 03/29/1983
• Est. Priority Date: 03/30/1981
• Status: Expired due to Term

• Current Assignee: Roche Diagnostics Corporation (Roche Holding AG)
• Original Assignee: Baker Instruments Corporation
• Inventors: Farina, Peter R., Golke, James R.
• Primary Examiner(s): Wiseman, Thomas G.
• Application Number:
  US06/248,689
• Time in Patent Office: 729 Days
• Field of Search: 435/4, 435/7, 435/18, 435/23, 435/24, 435/188, 435/199, 435/805, 435/810, 260/112, 260/121, 23/230 B, 424/8, 424/12
• US Class Current: 435/7.23
• CPC Class Codes: G01N 33/535 with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
• CPC Class Codes: G01N 33/542 with steric inhibition or signal modification, e.g. fluorescent quenching
• CPC Class Codes: G01N 33/58 involving labelled substances G01N33/53 takes precedence
• CPC Class Codes: Y10S 435/81 Packaged device or kit
• CPC Class Codes: Y10S 435/967 Standards, controls, materials, e.g. validation studies, buffer systems
• CPC Class Codes: Y10S 435/968 High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
• CPC Class Codes: Y10S 435/971 Capture of complex after antigen-antibody reaction
• CPC Class Codes: Y10S 435/975 Kit

Abstract

A highly sensitive, immunoassay method for determining the amount of an analyte in a sample containing a known analyte in an unknown concentration is provided. Sample; a polypeptide-labeled analog of the analyte, an antibody specific for said analyte, a polypeptide partner capable of non-covalently binding with the polypeptide-labeled analyte to form a complex having catalytic activity, and a substrate capable of being converted to a reporter molecule by the catalytic activity of said complex are brought together in a medium. The polypeptide-labeled analyte analog is capable of competitively binding to the antibody and the polypeptide partner, the antibody inhibiting the formation of a catalytically active complex in the absence of analyte, and the concentrations of the antibody, polypeptide partner and polypeptide-labeled analyte are such as to cause varying amounts of analyte to be directly related to the conversion of the substrate to the reporter molecule. Conversion of the substrate to the reporter molecule is then determined, and compared to conversions of substrate to reporter molecule obtained with known concentrations of the analyte.

Claims

1. A non-isotopic competitive binding assay method for determining the amount of an analyte in a sample containing a known analyte in an unknown concentration, which comprises the steps of:

(a) forming a reaction mixture by bringing together in a medium, (1) said sample, (2) polypeptide-labeled analyte, (3) an antibody specific for said analyte, (4) a polypeptide partner capable of non-covalently binding with the polypeptides of the polypeptide-labeled analyte to form a complex having catalytic activity, and (5) a substrate capable of being converted to a reporter molecule by the catalytic activity of said complex, said polypeptide-labeled analyte being capable of competitively binding to said antibody and to said polypeptide partner, said antibody inhibiting the formation of a catalytically active complex in the absence of analyte, the concentrations of said antibody, polypeptide partner and polypeptide-labeled analyte being such as to cause varying amounts of analyte in the sample to be directly related to the conversion of said substrate to said reporter molecule as a function of the catalytic activity of the complex;

(b) measuring the conversion of said substrate to said reporter molecule in said reaction mixture, and

(c) determining the amount of analyte in said sample by comparing the conversion of said substrate to said reporter molecule to conversions of said substrate to reporter molecule obtained with known concentrations of said analyte.

2. The method of claim 1 wherein the complex formed by the non-covalent binding of the polypeptide partner with the polypeptide-labeled analyte exhibits catalytic activity characteristic of a ribonuclease.

3. The method of claim 2 wherein said complex exhibits catalytic activity characteristic of ribonuclease A.

4. The method of claim 2 wherein the polypeptide label for the analyte is S-peptide and the polypeptide partner is S-protein.

5. The method of claim 2 wherein the polypeptide label for the analyte is S-protein and the polypeptide partner is S-peptide.

6. The method of claim 1 wherein at least one of the polypeptide label and the polypeptide partner were obtained by cleaving an enzyme.

7. The method of claim 6 wherein the polypeptide label and the polypeptide partner are cleaved fragments of a parent enzyme.

8. The method of claim 7 wherein the complex formed by the non-covalent binding of the polypeptide partner with the polypeptide-labeled analyte recovers at least 5% of the catalytic activity of said parent enzyme.

9. The method of claim 1 wherein the equilibrium constant for said complex is a value of about 10⁵ M^-1 to about 10¹¹ M^-1.

10. The method of claim 1 wherein said analyte has a molecular weight of at least about 100 to about 10⁶.

11. The method of claim 1 wherein said analyte is a member selected from the group consisting of a drug or its metabolite, an opiate, narcotic, hormone, steroid, vitamin, polypeptide hormone, tumor associated antigen, immunoglobin, enzyme, industrial pollutant, pesticide or its metabolite, food additive, herbicide or its metabolite, flavoring agent, and food poison.

12. The method of claim 1 wherein said analyte is a member selected from the group consisting of dilantin, ethosuximide, penobarbital, primidone, lidocaine, theophylline, morphine, codeine, heroin, marijuana, gentamicin, tobramycin, methotrexate, digitoxin, thyroxine, testosterone, cortisol, immunoglobulin, triiodothyronine, digoxin, folic acid, angiotensin II, progesterone, prostaglandin F2, estrogens, vitamin B₁₂, growth hormone, thyroid stimulating hormone, calcitonin, gastrin, luteinizing hormone, follicle stimulating hormone, glucagon, human chorionic gonadotropin, aldosterone and carcinoembryonic antigen.

13. The method of claim 12 wherein said analyte is dilantin.

14. The method of claim 12 wherein said analyte is thyroxine.

15. The method of claim 12 wherein said analyte is cortisol.

16. The method of claim 1 wherein said analyte is dilantin, the polypeptide label for dilantin is S-peptide and the polypeptide partner is S-protein.

17. The method of claim 1 wherein said analyte is thyroxine, the polypeptide label for thyroxine is S-peptide and the polypeptide partner is S-protein.

18. The method of claim 1 wherein said analyte is cortisol, the polypeptide label for cortisol is S-peptide and the polypeptide partner is S-protein.

19. The method of claim 1 wherein the antibody is present in a concentration sufficient to provide an inhibition of at least about 10%.

20. The method of claim 19 wherein the antibody is present in a concentration sufficient to provide an inhibition of at least about 50%.

21. The method of claim 1 wherein the substrate is present in a concentration such as to provide essentially linear rates over the rate measurement period.

22. The method of claim 1 wherein the substrate is present in a concentration of about 10^-4 to about 10^-2 molar.

23. The method of claim 1 wherein the substrate has the following structural formula:

##STR35## wherein B is a nucleotide base capable of assisting in hydrolysis of the phosphate ester at the 3'"'"'-position;

R is a moiety selected from the group consisting of umbelliferonyl, 4-methyl umbelliferonyl, 3-flavonyl, o-nitrophenyl, m-nitrophenyl, p-nitrophenyl, dinitrophenyl, cyanophenyl, acylphenyl, carboxyphenyl, phenylsulfonate, phenylsulfonyl and phenylsulfoxide;

R'"'"' is a moiety selected from the group consisting of hydrogen, alkyl, alkenyl, cycloalkyl, aryl, araalkyl, acyl, oxaalkyl, thioalkyl, oxacycloalkyl and thiocycloalkyl; and

R" is hydrogen or a cation selected from the group consisting of calcium, barium, lithium, sodium, ammonium, substituted ammonium and pyridinium.

24. The method of claim 23 wherein B is uracil, R is 4-methylumbelliferonyl, R'"'"' is acetyl and R" is a member selected from the group consisting of calcium, pyridinium and sodium.

25. The method of claim 1 wherein said rate is determined spectrophotometrically.

26. The method of claim 1 wherein said rate is determined fluorometrically.

27. A kit for use in carrying out an assay of an analyte, which comprises the following components:

(1) a polypeptide-labeled analyte, (2) an antibody specific for the analyte, (3) a polypeptide partner capable of non-covalently binding with the polypeptide of the polypeptide-labeled analyte to form a complex having catalytic activity and (4) a substrate capable of being converted to a reporter molecule by the catalytic activity of the complex wherein the polypeptide-labeled analyte, antibody, polypeptide partner and substrate are present in relative amounts sufficient for the determination of the analyte.

28. The kit of claim 27 which includes a set of standard analyte solutions which covers the anticipated concentration range for the analyte.

29. The kit of claim 27 which includes a buffer for pH adjustment for the assay.

30. The kit of claim 27 wherein each component is separately packaged.

31. The kit of claim 27 wherein the polypeptide-labeled analyte and the substrate are packaged together and the antibody and polypeptide partner are packaged together.

32. The kit of claim 27 wherein the antibody and polypeptide partner are packaged together.

33. The kit of claim 27 wherein the antibody and substrate are packaged together.

34. A non-isotopic competitive binding assay method for carrying out a heterogeneous immunoassay of a sample containing a known analyte present in an unknown concentration which comprises:

(a) forming a reaction mixture by bringing together in a medium (1) said sample, (2) a polypeptide-labeled analyte and (3) an antibody specific for said analyte;

(b) separating the antibody-bound, polypeptide-labeled analyte from the free polypeptide-labeled analyte;

(c) determining the amount of at least one of;

(1) the antibody-bound, polypeptide-labeled analyte and (2) the free polypeptide-labeled analyte by adding a polypeptide partner capable of non-covalently binding with the polypeptide of the polypeptide-labeled analyte to form a complex having catalytic activity and a substrate capable of being converted to a reporter molecule by the catalytic activity of said complex, by measuring the conversion of said substrate to reporter molecule, and

(d) determining the amount of analyte in said sample by comparing the conversion of said substrate to reporter molecule to conversions of said substrate to reporter molecule obtained with known concentrations of said analyte.